NUCIEN PHARMA(688189)2025-04-30 02:40Financial Performance - The company's operating revenue for Q1 2024 was ¥136,374,970.14, representing a decrease of 55.03% compared to the same period last year[5] - Net profit attributable to shareholders was ¥18,386,651.64, an increase of 46.71% year-over-year[5] - Basic earnings per share were ¥0.0670, reflecting a 46.61% increase from the prior year[5] - Total operating revenue for Q1 2024 was ¥136.37 million, a decrease of 55.1% compared to ¥303.23 million in Q1 2023[18] - Net profit for Q1 2024 reached ¥21.42 million, an increase of 49.0% from ¥14.36 million in Q1 2023[19] - Operating profit for Q1 2024 was ¥21.30 million, up 14.5% from ¥18.60 million in Q1 2023[19] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥36,863,557.07, showing a significant increase of 1,280.20% compared to the previous year[5] - Cash flow from operating activities for Q1 2024 was ¥36.86 million, significantly higher than ¥2.67 million in Q1 2023[21] - The company's cash and cash equivalents decreased to CNY 644,597,429.05 from CNY 665,760,897.54, reflecting a decline of 3.31%[13] - Cash and cash equivalents at the end of Q1 2024 totaled ¥543.31 million, down from ¥757.15 million at the end of Q1 2023[22] - The net cash flow from financing activities for Q1 2024 was -¥44.40 million, a decrease from a positive cash flow of ¥43.20 million in Q1 2023[22] Expenses and Cost Management - Research and development expenses totaled ¥16,512,853.64, down 51.46% year-over-year, with R&D expenses accounting for 12.11% of operating revenue, an increase of 0.89 percentage points[6] - Research and development expenses for Q1 2024 were ¥6.83 million, a decrease of 80.0% from ¥34.02 million in Q1 2023[18] - Sales expenses for Q1 2024 were ¥29.37 million, down 83.8% from ¥181.42 million in Q1 2023[18] - The increase in net profit was primarily due to a reduction in selling expenses and credit impairment losses during the reporting period[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,695,297,794.00, a decrease of 1.40% from the end of the previous year[6] - As of March 31, 2024, the total current assets amounted to CNY 1,245,613,160.93, a decrease of 2.06% from CNY 1,271,857,772.05 on December 31, 2023[13][14] - The total liabilities decreased to CNY 396,291,492.81 from CNY 433,803,361.39, a reduction of 8.66%[15] - The total equity attributable to shareholders increased to CNY 1,313,885,150.78 from CNY 1,303,495,883.51, reflecting a growth of 0.30%[15] Market Strategy and Conditions - The company adjusted its sales strategy in response to market conditions, leading to a decrease in sales prices for some core products, which contributed to the decline in operating revenue[8] - There are no applicable reminders regarding the company's operational situation during the reporting period[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,051[10] - The company has not reported any significant changes in shareholder relationships or actions among the top shareholders[11] Inventory and Receivables - Accounts receivable increased slightly to CNY 522,624,553.81 from CNY 520,668,671.48, showing a growth of 0.37%[13] - The inventory increased to CNY 31,399,170.09 from CNY 30,365,696.49, indicating a rise of 3.40%[14] Losses and Improvements - The company reported a net loss of CNY -148,033,393.96 for the period ending March 31, 2024, an improvement from a loss of CNY -166,420,045.60 in the previous period[15]